Candriam S.C.A. Has $99.76 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Candriam S.C.A. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,343,586 shares of the medical equipment provider’s stock after selling 28,331 shares during the period. Candriam S.C.A. owned 0.58% of Hologic worth $99,757,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the last quarter. Graypoint LLC grew its position in Hologic by 3.9% in the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after acquiring an additional 147 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after acquiring an additional 165 shares in the last quarter. Lincoln National Corp increased its stake in shares of Hologic by 4.0% during the 4th quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 178 shares during the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Hologic by 11.5% during the 4th quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock valued at $131,000 after purchasing an additional 189 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.7 %

Shares of HOLX stock opened at $81.57 on Friday. The stock has a market cap of $19.04 billion, a P/E ratio of 41.62, a price-to-earnings-growth ratio of 2.57 and a beta of 0.99. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The stock has a fifty day moving average price of $79.45 and a 200 day moving average price of $76.63. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.93 EPS. Analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Evercore ISI increased their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average price target of $87.60.

Insider Activity

In related news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.